Leptocarpin Suppresses Proliferation, Migration, and Invasion of Human Osteosarcoma by Targeting Type-1 Insulin-Like Growth Factor Receptor (IGF-1R)

被引:5
|
作者
Zheng, Shao-wei [1 ]
Wan, Wen-guo [2 ]
Miao, Hai-xiong [1 ]
Tang, Rui [3 ]
Wang, Bin [1 ]
Huang, Qi-zhi [1 ]
Liu, Wei-le [1 ]
Zheng, Jian-ping [1 ]
Chen, Chu-qun [1 ]
Zhong, Hao-bo [1 ]
Li, Sheng-fa [1 ]
Sun, Chun-han [1 ]
机构
[1] Huizhou 1st Peoples Hosp, Med Res Ctr, Dept Orthoped, Huizhou, Guangdong, Peoples R China
[2] Longmen Peoples Hosp Huizhou, Dept Orthoped, Huizhou, Guangdong, Peoples R China
[3] Southern Med Univ, Dept Cell Biol, Guangzhou, Guangdong, Peoples R China
来源
MEDICAL SCIENCE MONITOR | 2017年 / 23卷
关键词
Cell Migration Inhibition; Cell Proliferation; Osteosarcoma; CONFORMATIONAL-ANALYSIS; SESQUITERPENE LACTONE; BIOLOGICAL-ACTIVITY; PATHOGENESIS; CELLS;
D O I
10.12659/MSM.903427
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Background: Leptocarpin (LTC) has drawn much attention for suppressing tumor growth or reducing inflammation. However, the effect of LTC on osteosarcoma has rarely been reported. Our object was to determine whether LTC suppresses MG63 cell proliferation, migration, and invasion, and whether type-1 insulin-like growth factor receptor (IGF-1R) is one of the targets in LTC suppressing osteosarcoma. Material/Methods: Cytotoxicity of LTC was performed by use of a cell-counting kit-8 (CCK-8). RNA interference (RNAi) or pEABE-bleo IGF-1R plasmid were used for silencing or overexpressing IGF-1R, Western blot (WB) analysis was used for IGF-1R expression, CCK-8 for proliferation, and transwell assay for migration and invasion. Results: LTC (23.533 mu M) treatment for 48 h was taken as the 50% inhibiting concentration (IC50), which significantly (P<0.05) suppressed MG63 cells proliferation, migration, and invasion. LTC (IC50) obviously inhibited IGF-1R expression in MG63 cells, with similar effect to small interfering RNA (siRNA), while pEABE-bleo IGF-1R transfection overexpressed IGF-1R. siRNA silencing IGF-1R suppressed MG63 cells proliferation, migration, and invasion, while pEABE-bleo IGF-1R transfection was significantly (P<0.05) promoted. With or without siRNA or pEABE-bleo IGF-1R transfection, LTC (IC50) suppressed MG63 cells proliferation, migration, and invasion. The effect of LTC (IC50) combined with siRNA on suppressing MG63 cells proliferation, migration, and invasion was more obvious, while the effect of LTC (IC50) combined with pEABE-bleo IGF-1R transfection was less significant (P<0.05). Conclusions: LTC suppressed osteosarcoma proliferation, migration, and invasion by inhibiting IGF-1R expression. IGF-1R is one of the targets in LTC suppressing osteosarcoma.
引用
收藏
页码:4132 / 4140
页数:9
相关论文
共 50 条
  • [1] MONOCLONAL ANTIBODIES (MABS) TARGETING THE TYPE I INSULIN-LIKE GROWTH FACTOR RECEPTOR (IGF-1R)
    Chen, H. X.
    ANNALS OF ONCOLOGY, 2009, 20 : 17 - 17
  • [2] Insulin growth factor 1 like receptor (IGF-1R)
    Iyer, Gopal
    Price, James
    Bourgeois, Shay
    Armstrong, Eric
    Huang, Shyhmin
    Harari, Paul M.
    BMC CANCER, 2016, 16
  • [3] Insulin growth factor 1 like receptor (IGF-1R)
    Gopal Iyer
    James Price
    Shay Bourgeois
    Eric Armstrong
    Shyhmin Huang
    Paul M. Harari
    BMC Cancer, 16
  • [4] Antisense Oligonucleotide Targeting of Insulin-Like Growth Factor-1 Receptor (IGF-1R) in Prostate Cancer
    Furukawa, Junya
    Wraight, Christopher J.
    Freier, Susan M.
    Peralta, Eigan
    Atley, Lynne M.
    Monia, Brett P.
    Gleave, Martin E.
    Cox, Michael E.
    PROSTATE, 2010, 70 (02): : 206 - 218
  • [5] Targeting the insulin-like growth factor-1 receptor (IGF-1R) in the treatment of metastazising uveal melanoma
    Ericsson, CB
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2004, 45 : U514 - U514
  • [6] Insulin-like growth factor receptor (IGF-1R) in breast cancer subtypes
    Rinat Yerushalmi
    Karen A. Gelmon
    Samuel Leung
    Dongxia Gao
    Maggie Cheang
    Michael Pollak
    Gulisa Turashvili
    Blakes C. Gilks
    Hagen Kennecke
    Breast Cancer Research and Treatment, 2012, 132 : 131 - 142
  • [7] Insulin-like growth factor receptor (IGF-1R) in breast cancer subtypes
    Yerushalmi, Rinat
    Gelmon, Karen A.
    Leung, Samuel
    Gao, Dongxia
    Cheang, Maggie
    Pollak, Michael
    Turashvili, Gulisa
    Gilks, Blakes C.
    Kennecke, Hagen
    BREAST CANCER RESEARCH AND TREATMENT, 2012, 132 (01) : 131 - 142
  • [8] ImmunoPET imaging of insulin-like growth factor 1 receptor (IGF-1R) in pancreatic cancer
    England, Christopher
    Kamkaew, Anyanee
    Valdovinos, Hector
    Im, Hyung-Jun
    Barnhart, Todd
    Cai, Weibo
    JOURNAL OF NUCLEAR MEDICINE, 2016, 57
  • [9] The Synergistic Effect of Humanized Monoclonal Antibodies Targeting Insulin-Like Growth Factor 1 Receptor (IGF-1R) and Chemotherapy
    Sui, Ping
    Cao, Hongxin
    Meng, Long
    Hu, Pingping
    Ma, Honghai
    Du, Jiajun
    CURRENT DRUG TARGETS, 2014, 15 (07) : 674 - 680
  • [10] Clinical development of insulin-like growth factor receptor—1 (IGF-1R) inhibitors: At the crossroad?
    Andrea Gombos
    Otto Metzger-Filho
    Lissandra Dal Lago
    Ahmad Awada-Hussein
    Investigational New Drugs, 2012, 30 : 2433 - 2442